Phân tích y học hệ thống về chr1q-amp tiết lộ một trục PBX1-FOXM1 mới cho liệu pháp nhắm mục tiêu trong bệnh đa u tế bào máu

Watkins, 2020, Pervasive chromosomal instability and karyotype order in tumour evolution, Nature., 587, 126, 10.1038/s41586-020-2698-6 Priestley, 2019, Pan-cancer whole-genome analyses of metastatic solid tumours, Nature., 575, 210, 10.1038/s41586-019-1689-y Beroukhim, 2010, The landscape of somatic copy-number alteration across human cancers, Nature., 463, 899, 10.1038/nature08822 Pawlyn, 2017, Evolutionary biology of high-risk multiple myeloma, Nat Rev Cancer., 17, 543, 10.1038/nrc.2017.63 Avet-Loiseau, 2009, Prognostic significance of copy-number alterations in multiple myeloma, J Clin Oncol., 27, 4585, 10.1200/JCO.2008.20.6136 Shah, 2017, Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation, Leuk Lymphoma., 58, 1823, 10.1080/10428194.2016.1260126 Croft, 2021, Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial, Leukemia., 35, 2043, 10.1038/s41375-020-01096-y Walker, 2010, A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value, Blood., 116, e56, 10.1182/blood-2010-04-279596 Schmidt, 2019, Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone, Blood Cancer J., 9, 94, 10.1038/s41408-019-0254-0 Shah, 2018, Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients, Leukemia., 32, 102, 10.1038/leu.2017.179 Avet-Loiseau, 2012, Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival, J Clin Oncol., 30, 1949, 10.1200/JCO.2011.36.5726 Hanamura, 2006, Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation, Blood., 108, 1724, 10.1182/blood-2006-03-009910 Shaughnessy, 2005, Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma, Hematology., 10, 117, 10.1080/10245330512331390140 Shi, 2010, Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance, Oncotarget., 1, 22, 10.18632/oncotarget.105 Marchesini, 2017, ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma, Cancer Cell., 32, 88, 10.1016/j.ccell.2017.05.011 Teoh, 2020, IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification, Haematologica., 105, 1391, 10.3324/haematol.2019.221176 Shaughnessy, 2007, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood., 109, 2276, 10.1182/blood-2006-07-038430 Mani, 2009, BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells, Cancer Res., 69, 7577, 10.1158/0008-5472.CAN-09-0773 Zhang, 2002, Myeloid cell factor-1 is a critical survival factor for multiple myeloma, Blood., 99, 1885, 10.1182/blood.V99.6.1885 Teoh, 1997, MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells, Blood., 90, 1982, 10.1182/blood.V90.5.1982 Zang, 2015, Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH, Oncotarget., 6, 34276, 10.18632/oncotarget.5371 Fu, 2020, Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma, J Cancer., 11, 1182, 10.7150/jca.37313 Spanoudakis, 2009, Regulation of multiple myeloma survival and progression by CD1d, Blood., 113, 2498, 10.1182/blood-2008-06-161281 Kassambara, 2012, Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma, Haematologica., 97, 622, 10.3324/haematol.2011.046821 Alvarez-Benayas, 2021, Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma, Nat Commun., 12, 5450, 10.1038/s41467-021-25704-2 Iskander, 2021, Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia, Sci Transl Med., 13, eabf0113, 10.1126/scitranslmed.abf0113 Ponnusamy, The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma, Haematologica. Caputo, 2020, Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro, iScience., 24, 101989, 10.1016/j.isci.2020.101989 Keats, 2013, Interim analysis of the MMRF CoMMpass trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles, Blood., 122, 532, 10.1182/blood.V122.21.532.532 Wu, 2017, 3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations, Nat Commun., 8, 1937, 10.1038/s41467-017-01793-w Rao, 2014, A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping, Cell., 159, 1665, 10.1016/j.cell.2014.11.021 Sawyer, 2009, Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon, Br J Haematol., 147, 484, 10.1111/j.1365-2141.2009.07869.x Zhan, 2006, The molecular classification of multiple myeloma, Blood., 108, 2020, 10.1182/blood-2005-11-013458 Jin, 2018, Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma, Blood., 131, 2138, 10.1182/blood-2017-09-808063 Magnani, 2011, PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer, PLoS Genet., 7, e1002368, 10.1371/journal.pgen.1002368 Magnani, 2015, The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer, Oncotarget., 6, 21878, 10.18632/oncotarget.4243 Wang, 2017, Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer, Int J Cancer., 140, 2484, 10.1002/ijc.30680 Sarin, 2020, Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis, Leukemia., 34, 2754, 10.1038/s41375-020-0785-1 Mahdipour-Shirayeh, 2020, sciCNV: High-throughput paired profiling of transcriptomes and DNA copy number variations at single cell resolution, bioRxiv., 2020.02 Gu, 2018, Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma, BMC Cancer., 18, 1152, 10.1186/s12885-018-5015-0 Zhou, 2013, NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers, Cancer Cell., 23, 48, 10.1016/j.ccr.2012.12.001 Hegde, 2011, The transcription factor FOXM1 is a cellular target of the natural product thiostrepton, Nat Chem., 3, 725, 10.1038/nchem.1114 Hose, 2011, Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica., 96, 87, 10.3324/haematol.2010.030296 Bergsagel, 2005, Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood., 106, 296, 10.1182/blood-2005-01-0034 Shen, 2021, Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy, iScience, 24, 103297, 10.1016/j.isci.2021.103297 Li, 2020, Patterns of somatic structural variation in human cancer genomes, Nature., 578, 112, 10.1038/s41586-019-1913-9 Sawyer, 2005, Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q, Genes Chromosomes Cancer., 42, 95, 10.1002/gcc.20109 Black, 2015, Hypoxia drives transient site-specific copy gain and drug-resistant gene expression, Genes Dev., 29, 1018, 10.1101/gad.259796.115 Maura, 2021, Chromothripsis as a pathogenic driver of multiple myeloma, Semin Cell Dev Biol. Maclachlan, 2021, Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma, Nat Commun., 12, 5172, 10.1038/s41467-021-25469-8 Hanamura, 2021, Gain/amplification of chromosome arm 1q21 in multiple myeloma, Cancers (Basel)., 13, 256, 10.3390/cancers13020256 Liu, 2019, Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis, J Biol Chem., 294, 4572, 10.1074/jbc.RA118.006057 Calura, 2016, Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients, Oncotarget., 7, 2367, 10.18632/oncotarget.6151 Morton, 2019, Functional enhancers shape extrachromosomal oncogene amplifications, Cell., 179, 1330, 10.1016/j.cell.2019.10.039